160 related articles for article (PubMed ID: 9721791)
1. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis.
Garg PP; Kerlikowske K; Subak L; Grady D
Obstet Gynecol; 1998 Sep; 92(3):472-9. PubMed ID: 9721791
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Weiderpass E; Persson IR
J Natl Cancer Inst; 2002 Apr; 94(7):497-504. PubMed ID: 11929950
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study.
Hempling RE; Wong C; Piver MS; Natarajan N; Mettlin CJ
Obstet Gynecol; 1997 Jun; 89(6):1012-6. PubMed ID: 9170483
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and ovarian cancer risk: a meta-analysis.
Zhou B; Sun Q; Cong R; Gu H; Tang N; Yang L; Wang B
Gynecol Oncol; 2008 Mar; 108(3):641-51. PubMed ID: 18221779
[TBL] [Abstract][Full Text] [Related]
5. Postmenopausal hormone replacement therapy: scientific review.
Nelson HD; Humphrey LL; Nygren P; Teutsch SM; Allan JD
JAMA; 2002 Aug; 288(7):872-81. PubMed ID: 12186605
[TBL] [Abstract][Full Text] [Related]
6. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.
Li D; Ding CY; Qiu LH
Gynecol Oncol; 2015 Nov; 139(2):355-62. PubMed ID: 26232517
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma.
Sit AS; Modugno F; Weissfeld JL; Berga SL; Ness RB
Gynecol Oncol; 2002 Aug; 86(2):118-23. PubMed ID: 12144815
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study.
Gapstur SM; Morrow M; Sellers TA
JAMA; 1999 Jun; 281(22):2091-7. PubMed ID: 10367819
[TBL] [Abstract][Full Text] [Related]
9. Hormone replacement therapy and epithelial ovarian cancer: is there and association?
Riman T
J Br Menopause Soc; 2003 Jun; 9(2):61-8. PubMed ID: 12844427
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis.
Nanda K; Bastian LA; Hasselblad V; Simel DL
Obstet Gynecol; 1999 May; 93(5 Pt 2):880-8. PubMed ID: 10912438
[TBL] [Abstract][Full Text] [Related]
11. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
13. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
Khoo SK; Chick P
Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
[TBL] [Abstract][Full Text] [Related]
14. Estrogen replacement therapy and ovarian cancer.
Folsom AR; Anderson JP; Ross JA
Epidemiology; 2004 Jan; 15(1):100-4. PubMed ID: 14712153
[TBL] [Abstract][Full Text] [Related]
15. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations.
Schneider C; Jick SS; Meier CR
Climacteric; 2009 Dec; 12(6):514-24. PubMed ID: 19905903
[TBL] [Abstract][Full Text] [Related]
16. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Persson IR
Am J Epidemiol; 2002 Aug; 156(4):363-73. PubMed ID: 12181107
[TBL] [Abstract][Full Text] [Related]
18. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
20. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
